Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress

Core Insights - Moderna, Inc. has advanced mRNA-4359 into the Phase 2 portion of its ongoing Phase 1/2 trial [1] - Clinical, safety, and translational data from the study will be presented at the 2025 ESMO Congress in Berlin [1] - mRNA-4359 is an investigational cancer antigen therapy targeting immune evasion pathways PD-L1 and IDO1 [1] Company Developments - The trial evaluates mRNA-4359 in combination with pembrolizumab for checkpoint inhibitor-resistant/refractory melanoma patients [1] - The therapy aims to elicit antigen-specific T cell responses to directly kill tumor cells and deplete tumor suppressor cells [1]